{"id":10949,"date":"2020-01-09T16:40:36","date_gmt":"2020-01-09T15:40:36","guid":{"rendered":"https:\/\/udic.es\/?p=10949"},"modified":"2020-01-09T16:40:36","modified_gmt":"2020-01-09T15:40:36","slug":"an-amazing-phase-i-trial-in-parkinson","status":"publish","type":"post","link":"https:\/\/udic.es\/en\/an-amazing-phase-i-trial-in-parkinson\/","title":{"rendered":"An amazing Phase I trial in Parkinson"},"content":{"rendered":"

We have been activated in this trial that evaluates the safety of an innovative compound (antisense oligonucleotide) that aims to inhibit the activity of the LRKK2 gene and reduce the formation of alfasynuclein.<\/p>\n","protected":false},"excerpt":{"rendered":"

We have been activated in this trial that evaluates the safety of an innovative compound (antisense oligonucleotide) that aims to inhibit the activity of the LRKK2 gene and reduce the formation of alfasynuclein.<\/p>\n","protected":false},"author":4,"featured_media":9279,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[130],"tags":[],"class_list":["post-10949","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-parkinson-en"],"yoast_head":"\nAn amazing Phase I trial in Parkinson - UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica<\/title>\n<meta name=\"description\" content=\"We have been activated in this trial that evaluates the safety of an innovative compound (antisense oligonucleotide) that aims to inhibit the activity of\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/udic.es\/en\/an-amazing-phase-i-trial-in-parkinson\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"An amazing Phase I trial in Parkinson - UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica\" \/>\n<meta property=\"og:description\" content=\"We have been activated in this trial that evaluates the safety of an innovative compound (antisense oligonucleotide) that aims to inhibit the activity of\" \/>\n<meta property=\"og:url\" content=\"https:\/\/udic.es\/en\/an-amazing-phase-i-trial-in-parkinson\/\" \/>\n<meta property=\"og:site_name\" content=\"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci%c3%b3-Cl%c3%adnica-447149502490430\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-01-09T15:40:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/udic.es\/wp-content\/uploads\/2017\/09\/anagrama.png\" \/>\n\t<meta property=\"og:image:width\" content=\"182\" \/>\n\t<meta property=\"og:image:height\" content=\"138\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"SUSANA ANDRADE\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"SUSANA ANDRADE\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/udic.es\/en\/an-amazing-phase-i-trial-in-parkinson\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/udic.es\/en\/an-amazing-phase-i-trial-in-parkinson\/\"},\"author\":{\"name\":\"SUSANA ANDRADE\",\"@id\":\"https:\/\/udic.es\/#\/schema\/person\/7b598050df55fbeadbf6cdc699c31c03\"},\"headline\":\"An amazing Phase I trial in Parkinson\",\"datePublished\":\"2020-01-09T15:40:36+00:00\",\"dateModified\":\"2020-01-09T15:40:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/udic.es\/en\/an-amazing-phase-i-trial-in-parkinson\/\"},\"wordCount\":40,\"publisher\":{\"@id\":\"https:\/\/udic.es\/#organization\"},\"image\":{\"@id\":\"https:\/\/udic.es\/en\/an-amazing-phase-i-trial-in-parkinson\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/09\/anagrama.png\",\"articleSection\":[\"Parkinson\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/udic.es\/en\/an-amazing-phase-i-trial-in-parkinson\/\",\"url\":\"https:\/\/udic.es\/en\/an-amazing-phase-i-trial-in-parkinson\/\",\"name\":\"An amazing Phase I trial in Parkinson - UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica\",\"isPartOf\":{\"@id\":\"https:\/\/udic.es\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/udic.es\/en\/an-amazing-phase-i-trial-in-parkinson\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/udic.es\/en\/an-amazing-phase-i-trial-in-parkinson\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/09\/anagrama.png\",\"datePublished\":\"2020-01-09T15:40:36+00:00\",\"dateModified\":\"2020-01-09T15:40:36+00:00\",\"description\":\"We have been activated in this trial that evaluates the safety of an innovative compound (antisense oligonucleotide) that aims to inhibit the activity of\",\"breadcrumb\":{\"@id\":\"https:\/\/udic.es\/en\/an-amazing-phase-i-trial-in-parkinson\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/udic.es\/en\/an-amazing-phase-i-trial-in-parkinson\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/udic.es\/en\/an-amazing-phase-i-trial-in-parkinson\/#primaryimage\",\"url\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/09\/anagrama.png\",\"contentUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/09\/anagrama.png\",\"width\":182,\"height\":138,\"caption\":\"anagrama\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/udic.es\/en\/an-amazing-phase-i-trial-in-parkinson\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/udic.es\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"An amazing Phase I trial in Parkinson\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/udic.es\/#website\",\"url\":\"https:\/\/udic.es\/\",\"name\":\"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica\",\"description\":\"Unitat D'Investigaci\u00f3 Cl\u00ednica\",\"publisher\":{\"@id\":\"https:\/\/udic.es\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/udic.es\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/udic.es\/#organization\",\"name\":\"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica\",\"url\":\"https:\/\/udic.es\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/udic.es\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png\",\"contentUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png\",\"width\":408,\"height\":123,\"caption\":\"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica\"},\"image\":{\"@id\":\"https:\/\/udic.es\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci\u00f3-Cl\u00ednica-447149502490430\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/udic.es\/#\/schema\/person\/7b598050df55fbeadbf6cdc699c31c03\",\"name\":\"SUSANA ANDRADE\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/udic.es\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ae155cf03dc49fd596e9750d3cfd63ee?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ae155cf03dc49fd596e9750d3cfd63ee?s=96&d=mm&r=g\",\"caption\":\"SUSANA ANDRADE\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"An amazing Phase I trial in Parkinson - UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica","description":"We have been activated in this trial that evaluates the safety of an innovative compound (antisense oligonucleotide) that aims to inhibit the activity of","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/udic.es\/en\/an-amazing-phase-i-trial-in-parkinson\/","og_locale":"en_US","og_type":"article","og_title":"An amazing Phase I trial in Parkinson - UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica","og_description":"We have been activated in this trial that evaluates the safety of an innovative compound (antisense oligonucleotide) that aims to inhibit the activity of","og_url":"https:\/\/udic.es\/en\/an-amazing-phase-i-trial-in-parkinson\/","og_site_name":"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica","article_publisher":"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci%c3%b3-Cl%c3%adnica-447149502490430\/","article_published_time":"2020-01-09T15:40:36+00:00","og_image":[{"width":182,"height":138,"url":"https:\/\/udic.es\/wp-content\/uploads\/2017\/09\/anagrama.png","type":"image\/png"}],"author":"SUSANA ANDRADE","twitter_card":"summary_large_image","twitter_misc":{"Written by":"SUSANA ANDRADE"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/udic.es\/en\/an-amazing-phase-i-trial-in-parkinson\/#article","isPartOf":{"@id":"https:\/\/udic.es\/en\/an-amazing-phase-i-trial-in-parkinson\/"},"author":{"name":"SUSANA ANDRADE","@id":"https:\/\/udic.es\/#\/schema\/person\/7b598050df55fbeadbf6cdc699c31c03"},"headline":"An amazing Phase I trial in Parkinson","datePublished":"2020-01-09T15:40:36+00:00","dateModified":"2020-01-09T15:40:36+00:00","mainEntityOfPage":{"@id":"https:\/\/udic.es\/en\/an-amazing-phase-i-trial-in-parkinson\/"},"wordCount":40,"publisher":{"@id":"https:\/\/udic.es\/#organization"},"image":{"@id":"https:\/\/udic.es\/en\/an-amazing-phase-i-trial-in-parkinson\/#primaryimage"},"thumbnailUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/09\/anagrama.png","articleSection":["Parkinson"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/udic.es\/en\/an-amazing-phase-i-trial-in-parkinson\/","url":"https:\/\/udic.es\/en\/an-amazing-phase-i-trial-in-parkinson\/","name":"An amazing Phase I trial in Parkinson - UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica","isPartOf":{"@id":"https:\/\/udic.es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/udic.es\/en\/an-amazing-phase-i-trial-in-parkinson\/#primaryimage"},"image":{"@id":"https:\/\/udic.es\/en\/an-amazing-phase-i-trial-in-parkinson\/#primaryimage"},"thumbnailUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/09\/anagrama.png","datePublished":"2020-01-09T15:40:36+00:00","dateModified":"2020-01-09T15:40:36+00:00","description":"We have been activated in this trial that evaluates the safety of an innovative compound (antisense oligonucleotide) that aims to inhibit the activity of","breadcrumb":{"@id":"https:\/\/udic.es\/en\/an-amazing-phase-i-trial-in-parkinson\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/udic.es\/en\/an-amazing-phase-i-trial-in-parkinson\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/udic.es\/en\/an-amazing-phase-i-trial-in-parkinson\/#primaryimage","url":"https:\/\/udic.es\/wp-content\/uploads\/2017\/09\/anagrama.png","contentUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/09\/anagrama.png","width":182,"height":138,"caption":"anagrama"},{"@type":"BreadcrumbList","@id":"https:\/\/udic.es\/en\/an-amazing-phase-i-trial-in-parkinson\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/udic.es\/en\/"},{"@type":"ListItem","position":2,"name":"An amazing Phase I trial in Parkinson"}]},{"@type":"WebSite","@id":"https:\/\/udic.es\/#website","url":"https:\/\/udic.es\/","name":"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica","description":"Unitat D'Investigaci\u00f3 Cl\u00ednica","publisher":{"@id":"https:\/\/udic.es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/udic.es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/udic.es\/#organization","name":"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica","url":"https:\/\/udic.es\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/udic.es\/#\/schema\/logo\/image\/","url":"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png","contentUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png","width":408,"height":123,"caption":"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica"},"image":{"@id":"https:\/\/udic.es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci\u00f3-Cl\u00ednica-447149502490430\/"]},{"@type":"Person","@id":"https:\/\/udic.es\/#\/schema\/person\/7b598050df55fbeadbf6cdc699c31c03","name":"SUSANA ANDRADE","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/udic.es\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ae155cf03dc49fd596e9750d3cfd63ee?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ae155cf03dc49fd596e9750d3cfd63ee?s=96&d=mm&r=g","caption":"SUSANA ANDRADE"}}]}},"_links":{"self":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/posts\/10949"}],"collection":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/comments?post=10949"}],"version-history":[{"count":1,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/posts\/10949\/revisions"}],"predecessor-version":[{"id":10950,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/posts\/10949\/revisions\/10950"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/media\/9279"}],"wp:attachment":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/media?parent=10949"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/categories?post=10949"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/tags?post=10949"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}